A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMER¿S DISEASE DEMENTIA (THE DAYBREAK STUDY)

Intervention/treatment:
LY3314814 (AZD3293)/ FLORBETAPIR 18F/ FLUORODEOXYGLUCOSE 18F/ FLORTAUCIPIR 18F (18F-AV-1451)
Medical condition:
ALZHEIMER'S DISEASE
Protocol code:
I8D-MC-AZET
Control number:
194478
Status:
Closed
Approved:
May 26, 2016
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02783573
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
55 Years to 85 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Information Center
Organization
AstraZeneca
Phone:
1-877-240-9479
Sponsor
ELI LILLY CANADA INC

Locations

Alberta

University of Calgary
Calgary, Alberta, T2N 426

British Columbia

The Medical Arts Health Research Group
West Vancouver, British Columbia, V7T223

Nova Scotia

True North Clinical Research Halifax, LLC
Halifax, Nova Scotia, B3S1M7

Ontario

Bruyere Continuing Care
Ottawa, Ontario, K1N 5C8
Kawartha Regional Memory Clinic
Peterborough, Ontario, K9H2P4
Toronto Memory Program
Toronto, Ontario, M3B2S7
Toronto Sunnybrook Regional Cancer Center
Toronto, Ontario, M4N 3M5

Quebec

CSSS-Institut Universitaire Gériatric de Sherbrooke
Sherbrooke, Quebec, J1J3H5
Douglas Hospital and Research Centre
Verdun, Quebec, H4H 1R3
Q&T Research Sherbrooke Inc
Sherbrooke, Quebec, J1J 2G2
Recherches Neuro-Hippocampe Inc
Gatineau, Quebec, J8T 8J1

Results

See the results from the trial NCT02783573. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?